jRCT2061240014招募中不适用
Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction(EX6018-4979) (ARTEMIS )
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 275
- 主要终点
- Time to first occurrence of 3-point MACE
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Hospitalisationa for acute myocardial infarction with evidence of type 1 MI by invasive angiography performed at site with PCI capabilities.
- •ST-segment elevation myocardial infarction with all the following:
- •1.Relevant symptoms suggestive of cardiac ischaemia within 12 hours before hospitalisation or during hospitalisation.
- •2.ECG-changes (in the absence of left ventricular hypertrophy or left bundle branch block): ST-segment elevation at the J point in at least two contiguous lead >=0.25 mV in men <40 years, >=0.2 mV in men >=40 years, or >=0.15 mV in women in leads V2-V3: and/or >=0.1 mV in all other leads. or
- •Non-ST-segment myocardial infarction with all the following:
- •1.Relevant symptoms suggestive of cardiac ischaemia within 24 hours before hospitalisation or during hospitalisation.
- •2.Rise and/or fall in cardiac troponin I or T with at least one value above the 99th percentile upper reference limit.
- •Possibility for randomisation as early as possible after invasive procedure, and latest within 36 hours of hospitalisation (time 0) for STEMI, and latest within 48 hours of hospitalisation (time 0) for NSTEMI.
- •Presence of at least one of the following criteria (confirmed based on the participants medical records and/or medical history interview):
- •1.Relevant symptoms suggestive of cardiac ischaemia within 24 hours before hospitalisation or during hospitalisation.
- •2.Rise and/or fall in cardiac troponin I or T with at least one value above the 99th percentile upper reference limit.
- •Possibility for randomisation as early as possible after invasive procedure, and latest within 36 hours of hospitalisation (time 0) for STEMI, and latest within 48 hours of hospitalisation (time 0) for NSTEMI.
- •Presence of at least one of the following criteria (confirmed based on the participant's medical records and/or medical history interview):
- •Any prior MI.
- •Prior coronary revascularisation.c
- •Diabetes mellitus treated with glucose-lowering agent(s).
- •Known CKD (eGFR >=15 and <60 mL/min/1.73 m2).
- •Prior ischaemic stroke.
- •Known carotid disease or peripheral artery disease in the lower extremities.
- •Multivessel coronary artery diseased (current/prior).
- •For STEMI patients only: anterior MI at index AMI.
排除标准
- •Use of fibrinolytic therapy for treatment of the current AMI.
- •Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV.
- •Ongoing haemodynamic instability defined as any of the following:
- •Killip Class III or IV.
- •Sustained and/or symptomatic hypotension (systolic blood pressure <90 mmHg).
- •Severe kidney impairment defined as any of the following:
- •eGFR <15 mL/min/1.73 m
- •Chronic haemodialysis or peritoneal dialysis.
- •Known ALT >8 x ULN
- •Severe hepatic disease defined as at least one of the following:
- •Previously known or current hepatic encephalopathy (clinical evaluation).
- •Previously known or current ascites (clinical evaluation).
- •Jaundice (clinical evaluation).
- •Previous oesophageal/gastric variceal bleeding.
- •Known hepatic cirrhosis.
- •Major cardiac surgical (including but not restricted to coronary artery bypass graft surgery [CABG]), non-cardiac surgical, or major endoscopic procedureb (thoracoscopic or laparoscopic) within the past 60 days or any major surgical procedure planned at the time of randomisation or as treatment for the current AMI (CABG). Deferred (staged) percutaneous coronary intervention for a non-culprit vessel identified during the current AMI is allowed.
- •Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.c
- •Known (acute or chronic) hepatitis B or hepatitis C.
- •History or evidence of untreated latent tuberculosis (TB) such as (but not limited to):
- •History of a positive TB test or chest X-ray compatible with latent TB; and TB treatment initiated less than 28 days prior to randomisation.
- •Participants with TB risk factors but unwilling to undergo TB treatment if confirmed positive for latent TB based on central laboratory test at baseline (visit 2).
结局指标
主要结局
Time to first occurrence of 3-point MACE
A composite endpoint consisting of: - CV death - non-fatal MI - non-fatal stroke
次要结局
未报告次要终点
研究者
相似试验
招募中
3 期
Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammatiosystemische ontstekingenAtherosclerotic cardiovascular disease and chronic kidney disease1008220610038430NL-OMON54148ovo Nordisk120
招募中
3 期
Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammatioASCVD, CKD and systemic inflammationJPRN-jRCT2021210033Miyazaki Daisuke400
尚未招募
3 期
ARTEMIS - A research study to look at how ziltivekimab works compared to placeboin people with a heart attackCTRI/2024/06/068283ovo Nordisk A S
招募中
3 期
A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.heart failure with mildly reduced or preserved ejection fraction and systemic inflammationJPRN-jRCT2031230085Hirata Takashi120
已完成
3 期
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and InflammationChronic Kidney DiseaseNCT05021835Novo Nordisk A/S6,385